Breast Cancer

Latest News


Video Series


Latest Videos


Shorts

Why Are Younger Women Getting Diagnosed With Breast Cancer?
1:00
Why Are Younger Women Getting Diagnosed With Breast Cancer?
5 months ago
by
Shari B. Goldfarb, MD
Care Coordination Experiences in Breast Cancer
0:30
Care Coordination Experiences in Breast Cancer
6 months ago
by
Nicole Arrato, PhD
Exploring AI Use in Breast Radiation Oncology
0:34
Exploring AI Use in Breast Radiation Oncology
6 months ago
Is Proton Therapy Clinically Effective in Breast Cancer?
0:43
Is Proton Therapy Clinically Effective in Breast Cancer?
6 months ago
by
Chirag Shah, MD
The Technical Risks of Faster Radiation Treatments in Breast Cancer
0:55
The Technical Risks of Faster Radiation Treatments in Breast Cancer
7 months ago
by
Sunil W. Dutta, MD
Managing Immunotherapy-Related Toxicities in Breast Cancer
0:40
Managing Immunotherapy-Related Toxicities in Breast Cancer
7 months ago
by
Sarah Poland, MD
Can Preoperative Radiation Help Patients Skip Breast Cancer Surgery?
0:59
Can Preoperative Radiation Help Patients Skip Breast Cancer Surgery?
7 months ago
by
Parul Barry
How AI Is Revolutionizing Electronic Health Records
0:32
How AI Is Revolutionizing Electronic Health Records
7 months ago
by
Sunil W. Dutta, MD
Patrick Borgen, MD, discussed the impact that MRD and ctDNA have played on treatment selection for breast cancer, particularly regarding surgery.
1:17
Examining the Impact of ctDNA on Breast Cancer Surgery
7 months ago
by
Patrick I. Borgen, MD
Why Survivorship is the Next Phase of Cancer Research
0:41
Why Survivorship is the Next Phase of Cancer Research
7 months ago
by
Fumiko Chino, MD

Podcasts


CME Content


More News

Using the DISCERN tool, LLMs (ChatGPT and OpenEvidence) scored significantly higher than Google on breast pathology health information quality and reliability, with mean total DISCERN scores of 62.2 and 64.8 vs 35.9, supporting integration of AI tools for patient education.

A prospective subsidized breast biopsy and navigation program at a Kenyan referral hospital achieved same-day CNB in 100% of 104 patients with invasive breast carcinoma, revealing high rates of aggressive subtypes and median 8-month prediagnostic delays, with 16.35% mortality during follow-up.

In 278 patients with a positive family history of breast cancer followed for a median 96 months, local recurrence, regional recurrence, and CBC risk were comparable to general population rates by SIR analysis, with recurrence risk driven more by biological subtype than family history.

In 21 patients with metaplastic breast cancer receiving neoadjuvant chemotherapy, 48% achieved pCR—higher than prior estimates—with all pCR patients alive and disease-free at follow-up, suggesting modern regimens including pembrolizumab may improve outcomes in this chemoresistant subtype.

In this institutional retrospective review, 14.4% of clinically node-negative patients meeting SOUND trial criteria had nodal metastases on SLNB, underscoring the need for careful multidisciplinary decision-making before integrating axillary staging de-escalation into practice.

In 167 patients with HR+/HER2− breast cancer after neoadjuvant chemotherapy, lymphovascular invasion, number of positive sentinel nodes, and >50% positive sentinel nodes were the strongest predictors of high axillary burden; a nomogram was developed to guide axillary management decisions.